myFibroScan vs IVUSAID

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.

The IVUSAID App is a free educational mobile application which has been developed to teach medical professionals how to use intravascular ultrasound (IVUS) for PCI guidance based on the current guidelines using our extensive experience and large database of complex coronary cases. Despite the growing body of evidence for clinical benefits of IVUS-guided PCI, IVUS remains underutilized in much of the world including the United States. Challenges in image interpretation and education are among the barriers to widespread adoption of IVUS in everyday clinical practice. Mount Sinai Heart is a global leader within the field of interventional cardiology as well as mobile apps development. The myriad of cases and pathology which are seen in The Mount Sinai Cardiac Catheterization Laboratory make it the perfect center to educate medical professionals within this field. The Key Concepts section of IVUSAID describes principles of IVUS, image acquisition, and concepts of ultrasound behavior in various tissues. The Image Interpretation section of the app has dozens of representative cross-sectional images, videos, and descriptions of plaque types, stent apposition and expansion, artifacts, and more. A short video for each type of lesion or artifact and post-stent findings, in addition to an annotated representative cross section aims to overcome a major limitation of any article or book on IVUS which present a static image, since the actual IVUS pullback is dynamic. Twenty-one complex coronary cases demonstrate IVUS guidance in a variety of patient presentations and lesions including ACS, LM bifurcation, severely calcified lesions and calcified nodules, spontaneous coronary artery dissection, and malapposed stents as well as how IVUS was used to inform treatment decisions. An extensive quiz section helps deliver educational content in a more interactive format where answers are accompanied by detailed explanations and references. We hope that IVUSAID will help techs, fellows, and early-career physicians incorporate IVUS in their daily practice for stent sizing, post-stent optimization, and identification of appropriate treatment strategies.